# RC48-C016 (NCT05302284)

> A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05302284
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: RemeGen Co., Ltd.
- Conditions: Urothelial Carcinoma; HER2-expressing
- Interventions: RC48-ADC; Toripalimab; Gemcitabine; Cisplatin; Carboplatin
- Enrollment: 452
- Primary outcome: Progression-free survival (PFS), evaluated by independent review committee
- Primary outcome: Overall survival (OS)

## Indexed commentary on RC48-C016 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 14
- YouTube: 3
- Podcasts: 2
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=rc48-c016-nct05302284

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05302284", "email": "<work email>"}; the inbox owner confirms by the emailed link.